Recruiting
Phase 2

Dipyridamole

Sponsor:

Stanford University

Code:

NCT06824454

Conditions

Hypophosphatemia

Kidney Transplantation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dipyridamole 75 MG

Study Details

Brief summary:

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Conditions

Hypophosphatemia

Kidney Transplantation

Study ID

NCT06824454

Start date

May 15, 2025

Status verified date

Jun, 2026

Completion date

May, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult kidney transplant patients.
  • No known contraindications to Dipyridamole

Exclusion Criteria:

  • Contraindications to Dipyridamole.
  • Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
  • Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment Group

Participants receive Dipyridamole in addition to standard post-transplant care.

no intervention: Control Group

Participants in this group will receive standard post-transplant care without Dipyridamole.

Interventions

Dipyridamole 75 MG

Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.

Primary outcome measure

  • Change in Serum Phosphorus Levels After Dipyridamole Administration [ Time Frame: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio ]

Central Contacts and Locations

Locations

Stanford University

Recruiting

Stanford, California, United States, 94304

Contacts

Pari Waghela, MS

650-724-8441pariw@stanford.edu

Principal Investigator:

Stephan Busque, MD

More Information

Sponsor

Stanford University

Last update posted

Jun 11, 2026

Last verified

Jun, 2026

Keywords

  • Post-kidney transplant care
  • Dipyridamole
  • Renal phosphate loss
  • Serum phosphate levels
  • Phosphate supplementation
  • Transplant graft function
  • Kidney transplant complications

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Stanford University on 2026-06-11.